Skip to content

Effect of Intravenous Acetaminophen on Postoperative Morphine Consumption in Benign Open Abdominal Gynecological Surgeries: A double-blind, randomized, placebo-controlled trial

Effect of Intravenous Acetaminophen on Postoperative Morphine Consumption in Benign Open Abdominal Gynecological Surgeries: A double-blind, randomized, placebo-controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200512002
Enrollment
100
Registered
2020-05-12
Start date
2020-05-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing elective benign open abdominal gynecological surgery intravenous acetaminophen acetaminophen abdominal gynecological surgery hysterectomy postoperative pain benign gynecological surgery

Interventions

Each patient receives intravenous acetaminophen 15 mg/kg if less than 50 kg or 1000 mg if ≥ 50 kg. The first dose is given 30 minutes before surgery&#44
then three doses are given every 6 hours after the first dose.,The patient receives 100 ml of normal saline solution (NSS) intravenously instead of acetaminophen.
Experimental Drug,Placebo Comparator No treatment
acetaminophen group (A group),Placebo group (N group)

Sponsors

Faculty of Medicine, Chiang Mai University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18-65 years old 2. Patients who undergoing elective benign open abdominal gynecological surgery 3. American Society of Anesthesiologists (ASA) Class I-III

Exclusion criteria

Exclusion criteria: 1. Patients with known allergy to acetaminophen, parecoxib, sulfonamides, aspirin or opioids 2. Patients with either acute or chronic liver disease (defined as abnormal rising AST ALT, hypoalbuminemia, prolonged INR, or evidence from imaging diagnosis) 3. Patients with moderate to severe pain before surgery 4. Third trimester pregnant patients or lactation period 5. Patients receive any additional neuraxial block or peripheral nerve blocks for pain control 6. Patients with history of opioid abuse or chronic opioid use for greater than 3 months 7. Patients with suspected malignant gynecological disease intraoperatively and undergo extended lymph node dissection or complete surgical staging 8. Patients with contraindication to parecoxib (post CABG surgery, established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease, inflammatory bowel disease, Child-Pugh score ≥ 10, active peptic ulcer/ GI bleeding, known hypersensitivity to sulfonamides)

Design outcomes

Primary

MeasureTime frame
Cumulative postoperative morphine consumption within 24 hours 24 hours of postoperative Morphine consumption

Secondary

MeasureTime frame
length of hospital stay between two groups during hospitalization length of hospital stay,time to first flatulence and first defecation after surgery between two groups during hospitalization time to first flatulence and first defecation,time to first ambulation between two groups time to first ambulation time to first ambulation,Time to first dose morphine requirement time to first dose morphine time to first dose morphine,Adverse effects of acetaminophen, morphine, parecoxib during hospitalization patient report, observation,Postoperative pain at rest 1,4,8,12,16,20,24,48 hours postoperatively Numeric rating scale

Countries

Thailand

Contacts

Public ContactTanthip Jiruttikarnsakul

Faculty of Medicine, Chiang Mai University

tanthiptan@gmail.com0897629188

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026